SEC Company Response from HCA Healthcare, Inc. (HCA) (CIK 0000860730) (HCA) — Nov 2, 2005
HCA Healthcare, Inc. (HCA) (CIK 0000860730)
Date: Nov. 2, 2005 · CIK: 0000860730 · Accession: 0000950144-05-010996
AI Filing Summary & Sentiment
Referenced dates: October 27, 2005
Show Raw Text
CORRESP
1
filename1.htm
HCA INC.
J. Allen Overby
phone:(615) 742-6211
fax: (615) 742-2711
e-mail: aoverby@bassberry.com
BASS, BERRY & SIMS PLC
Attorneys at Law
A PROFESSIONAL LIMITED LIABILITY COMPANY
315 Deaderick Street, Suite 2700
Nashville, Tennessee 37238
(615) 742-6200
November 2, 2005
Via EDGAR and Facsimile (202) 772-9203
Jeffrey B. Werbitt
Attorney-Advisor
Office of Mergers and Acquisitions
Securities and Exchange Commission
Washington, DC 20549-0303
Re:
HCA Inc.
Schedule TO-I
Filed on October 14, 2005
File No. 005-41652
Dear Mr. Werbitt:
On behalf of HCA Inc. (the “Company”), and in response
to the Staff’s comments contained in your letter dated
October 27, 2005 (the “Comment Letter”), I submit
this letter containing the Company’s responses to the
Comment Letter. The Company’s responses to the Comment
Letter correspond to the numbered comments in the Comment
Letter. Amendment No. 2 to the Schedule TO-I (the
“Amendment”) was filed today with the Securities and
Exchange Commission via EDGAR.
OFFER TO PURCHASE
General
1.
Please provide a brief statement of the accounting treatment of
the offer. See Item 1004(a)(l)(xi) of Regulation M-A.
Jeffrey B. Werbitt
Securities and Exchange Commission
November 2, 2005
Page 2
RESPONSE:
The disclosure has been revised in accordance with the
comment.
2.
We note that HCA’s common stock has traded at a premium to
the base price for the past year, and during that time the stock
has also traded at a premium to the maximum offer price. Revise
the filing to highlight this fact to security holders. Also
highlight the risk that security holders who tender into this
offer, particularly those who tender at the price to be
determined in the offer, may receive less than they might
receive in an open market sale.
RESPONSE:
The disclosure has been revised in accordance with the
comment.
Summary Term Sheet, page 1
Once I have tendered Shares in the Offer, can I withdraw my
tendered Shares?, page 4
3.
You disclose that if not accepted for payment, the Shares
tendered may also be withdrawn at any time after 5:00 p.m., New
York City time on December 13, 2005.
Rule 13e-4(f)(2)(ii) Rule 13e-4(a)(3) defines
“business day” as the time period between 12:01 a.m.
and 12:00 midnight Eastern Time, other than Saturday, Sunday, or
a Federal holiday. Since your offer began on October 14,
2005, it does not appear that your offer complies with the time
period for additional withdrawal rights mandated by
Rule 13e-4(f)(2)(ii) and must be changed. Please revise
your Offer to Purchase here and throughout your document or
advise.
RESPONSE:
The disclosure has been revised in accordance with the
comment.
Forward Looking Statements. page 7
4.
The offer states that HCA “undertake[s] no obligation to
make any revision to the forward-looking statements contained in
this Offer to Purchase or to update them to reflect events or
circumstances occurring after the date of this Offer to
Purchase.” This disclosure appears to be inconsistent with
your obligation under
Jeffrey B. Werbitt
Securities and Exchange Commission
November 2, 2005
Page 3
Rules 13e-4(c)(3) and 13e-4(e)(3) to
amend the Schedule to reflect a material change in the
information previously disclosed. Please revise and confirm your
understanding.
RESPONSE:
The Company acknowledges the Staff’s position, and the
disclosure has been revised in accordance with the comment.
6. Conditions of the Offer, page 25
5.
We note that you will terminate the offer in the event a
condition is triggered, “regardless of the circumstances
giving rise to the event or events (including any actions or
omissions to act by us).” Allowing acts or omissions by the
company to trigger a condition to the offer may render the offer
illusory in that the circumstances giving rise to the existence
of a condition are within the control of the company. Please
revise and confirm your understanding of our position.
RESPONSE:
The Company acknowledges the Staff’s position, and the
disclosure has been revised in accordance with the comment.
6.
A tender offer may only be subject to conditions that are not
within the direct or indirect control of the bidder and are
drafted with sufficient specificity to allow for objective
verification that the conditions have been satisfied. Please
make the following changes to satisfy these requirements:
•
Revise the bullet points to avoid the reference to
“threatened” or “proposed” actions, as it is
unclear how this could be objectively determined;
•
Revise the bullet points to quantify the term “delay,”
as this term is problematic because of its breadth and lack of
specificity;
•
Avoid use of the term “could,” as this terms is too
vague to allow the shareholder to judge the scope of this
condition;
•
Revise the third and fourth bullet points to describe the
“contemplated benefits” or “contemplated future
conduct,” or cross-reference a specific section of the
document that discloses this information;
•
Clarify the language “any limitation, whether or not
mandatory” in bullet point 5(d) or otherwise revise to
provide a qualifier for the language;
Jeffrey B. Werbitt
Securities and Exchange Commission
November 2, 2005
Page 4
•
Revise bullet point 5(e) to clarify the “significant
decrease” in the market price of shares of your common
stock.
RESPONSE:
The disclosure has been revised in accordance with the
comment.
9. Source and Amount of Funds, page 28
7.
Confirm to us that when the financing is complete, you will
amend the Schedule TO to include the definitive terms of
and conditions to the financing pursuant to Item 1007(b)
and (d) of Regulation M-A and file any additional
relevant agreements as exhibits in accordance with
Item 1016(b) of Regulation M-A.
RESPONSE:
We supplementally advise the Staff that the Company currently
intends to amend its existing revolving credit facility and to
enter into definitive documentation for a new term facility on
the terms set forth in the Term Facility Commitment Letter (as
defined on page 30 of the Offer to Purchase) at least five
business days prior to the expiration of the offer. The Company
also currently intends to file an amendment to the
Schedule TO disclosing these events.
8.
See our last comment above. Be advised that it is our position
that a material change in the offer occurs when the offer
becomes financed, e.g., financing is obtained or the financing
condition is otherwise satisfied, and that, accordingly, five
days must remain in the offer or the offer must be extended upon
the satisfaction of the financing condition. In addition, this
information must be disseminated to shareholders. Please advise
of your intent in this regard.
RESPONSE:
See response to Comment No. 7 above.
11. Certain Information Concerning Us, page 35
9.
Your disclosure under “Incorporation by Reference”
suggests that you are attempting to forward incorporate by
reference. Please be advised that Schedule
Jeffrey B. Werbitt
Securities and Exchange Commission
November 2, 2005
Page 5
TO does not
specifically allow you to forward incorporate disclosure in
subsequently filed documents. In fact, doing so is inconsistent
with the technical requirements of General Instruction F of
Schedule TO and your obligation under
Rules 13e-4(c)(3) and 13e-4(e)(3) to amend the Schedule to
reflect a material change in the information previously
disclosed. Please revise your document to clarify.
RESPONSE:
The disclosure has been revised in accordance with the
comment.
13. Certain U.S. Federal Income Tax Consequences, page 42
10.
You are required to furnish a description of all of the
“material” federal tax consequences of the
transaction, rather than “certain” federal tax
consequences. Revise the heading and the first sentence of this
section to delete the word “[c]ertain” from the
heading, and to clarify that this section addresses the material
tax consequences of this transaction. See Item 1004(a)(xii)
of Regulation M-A.
RESPONSE:
The disclosure has been revised in accordance with the
comment.
11.
We note that you refer security holders to “consult [their]
own tax advisor to determine the federal, state, local, foreign
and other tax consequences” of participating in the offer.
Because security holders are entitled to rely on your tax
disclosure, it is inappropriate to include this apparent
disclaimer. Similar disclaimers should be revised throughout
your Offer to Purchase.
RESPONSE:
The disclosure has been revised in accordance with the
comment.
14. Extension of Offer; Termination; Amendments, page 46
12.
We note your disclosure that that you may “postpone”
payment for shares upon the occurrence of any conditions in this
section and in Section 7. Be advised that HCA may not
postpone acceptance or cancellation other than as a result of an
Jeffrey B. Werbitt
Securities and Exchange Commission
November 2, 2005
Page 6
extension of the offer. All conditions to the offer, other than
those conditions dependent upon the receipt of government
approvals, must be satisfied or waived prior to expiration of
the offer. Please revise your disclosure.
RESPONSE:
The disclosure has been revised in accordance with the
comment.
Letter of Transmittal
13.
We note your request that the security holder acknowledge that
they “understand” certain terms of the offer. It is
not appropriate to require security holders to attest to the
fact that they “understand” the terms of the offer as
such language may effectively operate as a waiver of liability.
Please delete this and other similar language throughout these
materials. To the extent that you have already circulated the
Election Form to security holders, please confirm that you will
not utilize the referenced language set forth in this form as a
waiver of liability against security holders.
RESPONSE:
The Company confirms that it will not utilize the referenced
language as a waiver of liability against security holders. In
addition, the disclosure has been revised in accordance with the
comment.
Please do not hesitate to contact me at the above telephone
number if you have any questions or further comments. Thank you
in advance for your prompt attention to this matter.
Sincerely,
/s/ J. Allen Overby